Rodriguez Javier 4

What Happened Javier Rodriguez, Chief Legal Officer, Senior Vice President and Corporate Secretary of BioXcel Therapeutics (BTAI), reported conversion/exercise of derivatives (RSUs) into common stock. He acquired 33 shares on 2026-03-14 and 35 shares on 2026-03-15 (total 68 shares). The filing also shows matching derivative dispositions of 33 and 35 shares reported at $0.00 (no cash value reported).

Key Details

• Transaction dates: 2026-03-14 (33 shares) and 2026-03-15 (35 shares).
• Reported prices/values: Acquisitions listed as N/A; matching derivative dispositions reported at $0.00.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnotes: F1 notes each RSU converts to one share. F2 and F3 describe RSU grants (521 RSUs granted 3/14/2022 and 562 RSUs granted 3/15/2023) with multi-year vesting schedules.
• Filing: Form 4 filed 2026-03-16 (appears filed promptly after the reported transactions).

Context

• Code M (exercise/conversion of derivative) and the footnotes indicate these were RSU vesting/conversion events. The matching $0 derivative dispositions are consistent with common net settlement or share-withholding practices when RSUs vest (i.e., shares converted and some shares are not delivered as part of withholding), but the filing itself shows no cash sale.
• Such transactions typically reflect scheduled vesting of awards rather than an open-market buy or sell; they do not by themselves indicate a change in insider sentiment.